GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-02. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
== Hydrogen-7 == 7H (atomic mass 7.05275(108) Da) has one proton and six neutrons. It was first synthesized in 2003 by a group of Russian, Japanese and French scientists at Riken's Radioactive Isotope Beam Factory by bombarding hydrogen with helium-8 atoms; all six of the helium-8's neutrons were donated to the hydrogen nucleus. The two remaining protons were detected by the "Riken telescope", a device made of several layers of sensors, positioned behind the target of the RI Beam cyclotron. 7H has a half-life of 652(558) ys (6.52(558)×10−22 s).
== Biosynthesis == The apelin gene encodes a pre-proprotein of 77 amino acids, with a signal peptide in the N-terminal region. After translocation into the endoplasmic reticulum and cleavage of the signal peptide, the proprotein of 55 amino acids may generate several active fragments: a 36 amino acid peptide corresponding to the sequence 42-77 (apelin 36), a 17 amino acid peptide corresponding to the sequence 61-77 (apelin 17) and a 13 amino acid peptide corresponding to the sequence 65-77 (apelin 13). This latter fragment may also undergo a pyroglutamylation at the level of its N-terminal glutamine residue. However the presence and/or the concentrations of those peptides in human plasma has been questioned. Recently, 46 different apelin peptides ranging from apelin 55 (proapelin) to apelin 12 have been identified in bovine colostrum, including C-ter truncated isoforms.
== Climate == Like the rest of Wales and the British Isles, Holyhead has a maritime climate (Cfb according to the Köppen climate classification) with cool summers and mild winters, and often high winds exacerbated by its location by the Irish Sea. The nearest official weather observation station is at RAF Valley, about five miles (eight kilometres) southeast of the town centre. On 23 November 1981, Holyhead was struck by two tornadoes during the record-breaking 1981 United Kingdom tornado outbreak. One of the tornadoes, rated as an F2/T4 tornado, was the strongest recorded out of 104 tornadoes in the entire outbreak, causing damage to around 20 properties in Holyhead and destroying a mobile home.
== Prognosis == The life expectancy of patients with homocystinuria is reduced only if untreated. It is known that before the age of 30, almost one quarter of patients die as a result of thrombotic complications (e.g., heart attack).
Sources: en.wikipedia.org
=== Primary ad agency === In April 2018, Dunkin' named BBDO as their primary advertising agency. This replaced Hill Holliday, which had been producing print, digital, broadcast, and billboard advertising for almost twenty years. Hill Holliday was the agency responsible for the tagline "America Runs on Dunkin'". ARC/Leo Burnett was also named to lead all in-store promotions.
== External links == True Anatomy for New Ways of Teaching von Hagens Plastination offers one-of-a-kind, real human teaching specimens! Plastination technique, on Body Worlds page Plastination website by Dr. Selcuk Tunali Laboratory of Plastination & Anatomical Techniques, Universidad de La Frontera, Temuco, Chile (Dr. Nicolas E. Ottone) Plastination Models Inc. Plastination in India by Dr. N. M. Shama Sundar. Plastination: Silicone Impregnation of Specimens (the standard S10 technique) Plastination: The Sheet Plastination Technique International Society for Plastination The New Plastination Index Online The New Plastination Index on-line: Subject Index "Exhibit Human" a documentary on plastination by Aaron Edell Learn About PCOM's Plastination Process Plastination
Major production sites include Sulawesi, Indonesia, the Sudbury region of Canada, New Caledonia in the Pacific, Western Australia, and Norilsk, Russia. Nickel is one of four elements (the others are iron, cobalt, and gadolinium) that are ferromagnetic at about room temperature. Alnico permanent magnets based partly on nickel are of intermediate strength between iron-based permanent magnets and rare-earth magnets. The metal is used chiefly in alloys and corrosion-resistant plating. About 68% of world production is used in stainless steel. A further 10% is used for nickel-based and copper-based alloys, 9% for plating, 7% for alloy steels, 3% in foundries, and 4% in other applications such as in rechargeable batteries, including those in electric vehicles (EVs). Nickel is widely used in coins, though nickel-plated objects sometimes provoke nickel allergy. As a compound, nickel has a number of niche chemical manufacturing uses, such as a catalyst for hydrogenation, cathodes for rechargeable batteries, pigments and metal surface treatments. Nickel is an essential nutrient for some microorganisms and plants that have enzymes with nickel as an active site.
=== 1979 === 5 August: Alison Chambers (16). Chambers had been placed into foster care at the age of 14 and had repeatedly absconded from Jordan's Brook House. She became acquainted with the Wests in mid-1979, and Fred later claimed to his solicitor that Chambers had died as a result of Rose becoming "too bloody vicious" with her. Her dismembered body, missing several bones and with a leather belt looped beneath her jaw and tied at the top of her head, was buried in the garden of Cromwell Street. This was the final murder where a definite sexual motive was established.
=== Insect welfare === There are concerns that insect farming may involve large-scale suffering. Although the ability of insects to suffer is debated, the number of animals involved is particularly large. As of 2023, there are no widely adopted welfare standards in the industry.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.